Drug Patch Manufacturers Can Skip Quality By Design Approach, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Final guidance softens a recommendation that manufacturers of transdermal and transmucosal drug delivery systems and topical patches use a Quality by Design approach.
You may also be interested in...
Use QbD to Get Through Rough Patch, FDA Tells Transdermal Makers
FDA officials say that there are “scientific gaps” in how transdermal patches are developed, manufactured and regulated, and urged manufacturers to adopt quality- by-design methods to help bridge these gaps and to better ensure product quality and safety.
Use QbD to Get Through Rough Patch, FDA Tells Transdermal Makers
FDA officials say that there are “scientific gaps” in how transdermal patches are developed, manufactured and regulated, and urged manufacturers to adopt quality- by-design methods to help bridge these gaps and to better ensure product quality and safety.
NuPathe Must Patch Together New Zelrix Launch Timetable After "Complete Response" Letter
FDA had questions related to chemistry, manufacturing and safety of migraine patch, company said.